Immucell Stock Price, News & Analysis

ImmuCell Corporation (NASDAQ: ICCC) has announced it will release its unaudited financial results for Q1 2025 after market close on May 14, 2025. The company will host a conference call on May 15, 2025, at 9:00 AM ET to discuss the results. The company maintains its preliminary sales results disclosed on April 8, 2025, with no anticipated changes. The Q1 2025 Form 10-Q filing is expected on May 14, 2025.

ImmuCell, focused on dairy and beef cattle health products, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for subclinical mastitis treatment in dairy cows. An updated Corporate Presentation will be available on the company's website after market close on May 14.

ImmuCell (ICCC) reported record-breaking preliminary sales results for Q1 2025, achieving $8.1 million in quarterly sales, an 11% increase from Q1 2024. The company's performance showed strong growth with six-month sales reaching $15.8 million (up 28%) and twelve-month sales hitting $27.3 million (up 28%) through March 31, 2025.

The Q1 2025 results exceeded the previous record set in Q4 2024 by 4%, helping reduce the order backlog to $4.0 million from $4.4 million. Production output during Q1 2025 reached approximately 108% of the company's estimated $30 million annual capacity.

Additionally, ImmuCell is initiating Investigational Product use of Re-Tain® through a controlled launch to test market acceptance. The company submitted its Non-Administrative New Animal Drug Application in January 2025, though approval remains pending facility inspections at their contract manufacturer.

ImmuCell (Nasdaq: ICCC) has appointed Timothy C. Fiori as its new Chief Financial Officer. Fiori brings approximately 24 years of finance and commercial operating experience from IDEXX Laboratories in Westbrook, Maine. He holds a B.S. in Finance from the University of Maine (2001).

The company, which develops and manufactures products for dairy and beef cattle health, sees this hire as a strategic move in its growth plan. CEO Michael F. Brigham highlighted that Fiori will help leverage personnel, improve standard costing and financial reporting systems, and enhance business efficiencies.

ImmuCell's key products include First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.

ImmuCell (Nasdaq: ICCC) has announced the initiation of Investigational Product use of Re-Tain®, its novel treatment for subclinical mastitis in dairy cows. This controlled launch will help test market acceptance and utilize available inventory before shelf-life expiration, though it's not expected to generate significant revenue or profit.

The company submitted its Non-Administrative New Animal Drug Application (NADA) in early January 2025, including its fourth CMC Technical Section submission along with minor technical sections for All Other Information and Product Labeling. The critical path to NADA approval remains contingent on clearing inspectional observations at the facilities of ImmuCell's contract manufacturer.

This investigational strategy allows ImmuCell to gather product performance data while awaiting full NADA approval. Re-Tain® aims to provide an alternative to traditional antibiotics without FDA-required milk discard or pre-slaughter withdrawal label restrictions.

ImmuCell (ICCC) reported strong financial results for Q4 and full-year 2024, with product sales increasing 52% to $7.8 million in Q4 and $26.5 million for the full year. The company demonstrated significant operational improvements with gross margin expanding to 37% in Q4 2024 from 25% in Q4 2023.

The company achieved positive EBITDA of $1.3 million in Q4 2024, compared to negative ($311,000) in Q4 2023. Net income for Q4 2024 was $515,000 ($0.06 per share), versus a loss of ($1.14 million) in Q4 2023. Cash position strengthened to $3.8 million, up from $979,000 year-over-year.

ImmuCell has operated without contamination issues since April 2024, focusing on improving production yields and gross margins. The company continues to work towards FDA approval for Re-Tain®, with a recent submission of the Non-Administrative NADA in January 2025.

ImmuCell (Nasdaq: ICCC) has announced it will release its unaudited financial results for Q4 and full-year 2024 after market close on February 25, 2025. The company will host a conference call on February 26, 2025, at 9:00 AM ET to discuss these results.

The company confirms there are no changes to the preliminary sales results disclosed on January 9, 2025, and expects to file its Annual Report on Form 10-K by March 31, 2025. An updated Corporate Presentation will be available on the company's website after market close on February 25, 2025.

ImmuCell, which focuses on developing products for dairy and beef cattle health, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for treating subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold restrictions.

ImmuCell (Nasdaq: ICCC) has announced the settlement of an insurance claim related to production contamination events that occurred from late 2022 through April 2024. The company has accepted a settlement of $426,587, which is in addition to the $250,000 previously paid and recognized during the third quarter of 2023.

The company will host a conference call on February 26, 2025, at 9:00 AM ET to discuss unaudited financial results for Q4 and full-year 2024. ImmuCell manufactures First Defense® for newborn dairy and beef calves and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold restrictions.

ImmuCell (ICCC) reported strong preliminary, unaudited sales results for Q4 and full year 2024. The company achieved total sales of $7.8 million in Q4 2024, a 52% increase from $5.1 million in Q4 2023. Full-year 2024 sales reached $26.5 million, up 52% from $17.5 million in 2023.

Production output during Q4 2024 reached 103% of the company's estimated full capacity of $30 million per year. This helped reduce the order backlog to $4.4 million as of January 1, 2025, down from $9.4 million a year earlier. The company attributes the current backlog to strong demand as distributors replenish buffer stocks and end-users place orders ahead of peak calving season.

ImmuCell also reported progress on Re-Tain®, with the recent submission of its Non-Administrative NADA to the FDA, including the fourth CMC Technical Section submission and discussions about expedited review.